Guideline Recommendations for Management of Severe Aortic Regurgitation in Hypertensive Patients

Blood‑Pressure Management in Chronic Severe AR

• First‑line antihypertensive therapy should be an ACE inhibitor or an ARB when systolic blood pressure exceeds 140 mm Hg (European Society of Cardiology, Class I, Level B). 3
• Dihydropyridine calcium‑channel blockers (e.g., nifedipine) are acceptable alternatives; they reduce left‑ventricular volume and mass and improve ventricular performance (American College of Cardiology, Class IIa, Level B). 1
• These vasodilators lower systolic pressure without markedly reducing diastolic pressure, preserving coronary‑perfusional driving pressure (American College of Cardiology, Class IIa, Level B). 5
• Beta‑blockers should be avoided as first‑line agents in chronic AR because bradycardia prolongs diastolic filling time and can increase regurgitant volume (American College of Cardiology, Class III‑Harm, Level C). 6
• Beta‑blockers may paradoxically raise systolic pressure by increasing trans‑aortic stroke volume when heart rate falls (American College of Cardiology, Class IIb, Level C). 8
• Beta‑blockers are permissible only in the presence of reduced ejection fraction, prior myocardial infarction, significant arrhythmias, or angina (American College of Cardiology, Class IIb, Level C). 5

Indications for Aortic‑Valve Replacement (AVR)

Symptomatic Patients

• AVR is indicated for every patient with severe AR who has symptoms (dyspnea, angina, or heart‑failure signs), irrespective of left‑ventricular systolic function (European Society of Cardiology, Class IB, Level B). 3

Asymptomatic Patients with Left‑Ventricular Dysfunction

• AVR is recommended when left‑ventricular ejection fraction falls below 50‑55 % in the absence of another cause of dysfunction (European Society of Cardiology, Class IB, Level B). 4
• AVR is reasonable when left‑ventricular end‑systolic dimension exceeds 50 mm (or 45 mm per some guidelines) even if ejection fraction remains preserved (European Society of Cardiology, Class IIa, Level B). 4
• Progressive left‑ventricular dilation into the severe range (end‑diastolic dimension > 65 mm) may also justify surgery (European Society of Cardiology, Class IIa, Level C). 3

Asymptomatic Patients with Normal LV Function

• Serial echocardiographic surveillance every 6–12 months is advised for severe, asymptomatic AR with normal LV function (European Society of Cardiology, Class IIa, Level C). 4
• If a notable decline in ejection fraction or increase in LV size is detected, repeat imaging at 3–6‑month intervals is recommended (European Society of Cardiology, Class IIa, Level C). 3

Role and Limitations of Medical Therapy

• For asymptomatic patients with chronic severe AR and hypertension (SBP > 140 mm Hg), antihypertensive treatment is recommended (European Society of Cardiology, Class IB‑NR, Level B). 3
• When symptoms or LV dysfunction exist but surgical risk is prohibitive, guideline‑directed medical therapy (ACE‑I/ARB ± sacubitril/valsartan) is advised (European Society of Cardiology, Class IIa, Level B). 4
• Medical therapy may provide temporary symptomatic relief when surgery is not feasible, but it does not replace definitive AVR (European Society of Cardiology, Class IIb, Level C). 3
• Long‑term outcomes (e.g., time to valve replacement) with vasodilator therapy are variable and not consistently favorable (American College of Cardiology, Level C). 2
• There is no robust evidence that vasodilators reduce AR severity or modify disease trajectory in patients without systemic hypertension (American College of Cardiology, Level C). 9
• Theoretical concerns that excessive diastolic‑pressure reduction could impair coronary perfusion lack outcome data (American College of Cardiology, Level C). 5

Echocardiographic Markers Defining Severe AR (Monitoring)

(All thresholds endorsed by the European Society of Cardiology) 3

Critical Pitfalls to Avoid

• Do not postpone AVR in symptomatic patients while attempting medical optimization; surgery should not be delayed (European Society of Cardiology, Class III‑Harm, Level C). 7
• Do not use beta‑blockers as first‑line antihypertensives in chronic AR because they may worsen regurgitation (American College of Cardiology, Class III‑Harm, Level C). 6
• Intra‑aortic balloon counter‑pulsation is contraindicated in acute severe AR (European Society of Cardiology, Class III‑Harm, Level C). 10
• Do not wait for ejection fraction to drop below 50 % before considering surgery; earlier intervention at EF < 55 % or LVESD > 50 mm is acceptable (European Society of Cardiology, Class IIa, Level B). 4

Management of Acute Severe AR

• Acute severe AR constitutes a surgical emergency; urgent AVR is required (European Society of Cardiology, Class I, Level B). 10
• Short‑term medical therapy (afterload‑reducing vasodilators and inotropes) may stabilize hemodynamics pre‑operatively, but must not delay definitive surgery, especially in the setting of hypotension, pulmonary edema, or low‑flow states (European Society of Cardiology, Class IIa, Level C). 3
• Vasodilators and inotropes are appropriate for pre‑operative hemodynamic support (American College of Cardiology, Level C). 10